CN106170284A - 具有控释特征的装载肽的plga微球体的制备 - Google Patents

具有控释特征的装载肽的plga微球体的制备 Download PDF

Info

Publication number
CN106170284A
CN106170284A CN201480077756.4A CN201480077756A CN106170284A CN 106170284 A CN106170284 A CN 106170284A CN 201480077756 A CN201480077756 A CN 201480077756A CN 106170284 A CN106170284 A CN 106170284A
Authority
CN
China
Prior art keywords
microspheres
water
peptide
temperature
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480077756.4A
Other languages
English (en)
Chinese (zh)
Inventor
E·卡拉瓦斯
E·科特里斯
K·米尼亚蒂
S·希塔多
G·帕帕尼古拉乌
T·曼特尔丽萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmathen SA
Original Assignee
Pharmathen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen SA filed Critical Pharmathen SA
Priority to CN202111524730.8A priority Critical patent/CN114191538A/zh
Publication of CN106170284A publication Critical patent/CN106170284A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201480077756.4A 2014-03-31 2014-03-31 具有控释特征的装载肽的plga微球体的制备 Pending CN106170284A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111524730.8A CN114191538A (zh) 2014-03-31 2014-03-31 具有控释特征的装载肽的plga微球体的制备

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/000858 WO2015149820A1 (en) 2014-03-31 2014-03-31 Preparation of peptide loaded plga microspheres with controlled release characteristics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111524730.8A Division CN114191538A (zh) 2014-03-31 2014-03-31 具有控释特征的装载肽的plga微球体的制备

Publications (1)

Publication Number Publication Date
CN106170284A true CN106170284A (zh) 2016-11-30

Family

ID=50486884

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111524730.8A Pending CN114191538A (zh) 2014-03-31 2014-03-31 具有控释特征的装载肽的plga微球体的制备
CN201480077756.4A Pending CN106170284A (zh) 2014-03-31 2014-03-31 具有控释特征的装载肽的plga微球体的制备

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202111524730.8A Pending CN114191538A (zh) 2014-03-31 2014-03-31 具有控释特征的装载肽的plga微球体的制备

Country Status (23)

Country Link
US (1) US9943483B2 (enExample)
EP (1) EP3125871B1 (enExample)
JP (1) JP6494657B2 (enExample)
KR (1) KR102218655B1 (enExample)
CN (2) CN114191538A (enExample)
AU (1) AU2014389015B2 (enExample)
BR (1) BR112016022550B1 (enExample)
CA (1) CA2944561C (enExample)
CY (1) CY1124037T1 (enExample)
DK (1) DK3125871T3 (enExample)
EA (1) EA032580B1 (enExample)
ES (1) ES2837044T3 (enExample)
HR (1) HRP20210058T1 (enExample)
HU (1) HUE052289T2 (enExample)
LT (1) LT3125871T (enExample)
MX (1) MX371139B (enExample)
PL (1) PL3125871T3 (enExample)
PT (1) PT3125871T (enExample)
RS (1) RS61209B1 (enExample)
SI (1) SI3125871T1 (enExample)
SM (1) SMT202000692T1 (enExample)
WO (1) WO2015149820A1 (enExample)
ZA (1) ZA201607413B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106499A (zh) * 2014-11-02 2017-08-29 纳诺精密医疗有限公司 用于延长释放治疗剂的可植入医药装置
CN108113975A (zh) * 2018-02-02 2018-06-05 中国人民解放军军事科学院军事医学研究院 一种基于涡漩振荡器的plga微球制备方法及其应用
CN109106688A (zh) * 2018-08-22 2019-01-01 丽珠医药集团股份有限公司 一种醋酸奥曲肽微球的制备方法
CN114174385A (zh) * 2020-05-08 2022-03-11 M技术株式会社 主剂均匀分散的微球和含有其的缓释制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2928500B1 (en) 2012-12-04 2019-03-06 Phosphorex Inc. Microparticles and nanoparticles having negative surface charges
US20230022463A1 (en) * 2014-11-02 2023-01-26 Nano Precision Medical, Inc. Implantable medical devices for extended release of therapeutic agents
KR102068578B1 (ko) * 2016-08-16 2020-01-21 중앙대학교 산학협력단 세포전달을 위한 다공성 마이크로스피어 및 이의 제조방법
EP3551575A4 (en) * 2016-12-12 2020-08-12 Phosphorex, Inc. MICROPARTICLE AND NANOPARTICLE WITH NEGATIVE SURFACE CHARGES
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법
JP7600528B2 (ja) * 2020-03-16 2024-12-17 株式会社リコー 粒子の製造方法
JP6810502B1 (ja) * 2020-05-08 2021-01-06 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
KR20220163418A (ko) * 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116139256A (zh) * 2023-03-14 2023-05-23 复旦大学附属肿瘤医院 生长抑素/生长抑素类似物缓释膜及其制备方法和应用
CN120919405B (zh) * 2025-10-14 2025-12-16 渼颜空间生物科技(吉林)有限公司 一种pha微球、及其制备方法、含其制剂和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
WO2005110369A2 (en) * 2004-04-30 2005-11-24 American Pharmaceutical Partners, Inc. Sustained-release microspheres and methods of making and using same
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
WO2005110369A2 (en) * 2004-04-30 2005-11-24 American Pharmaceutical Partners, Inc. Sustained-release microspheres and methods of making and using same
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R.JEYANTHI ET AL.: "Effect of solvent removal technique on the matrix characteristics of polylactide/glycolide microspheres for peptide delivery", 《JOURNAL OF CONTROLLED RELEASE》 *
RAHUL C. MEHTA ET AL.: "Biodegradable microspheres as depot system for parenteral delivery of peptide drugs", 《JOURNAL OF CONTROLLED RELEASE》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106499A (zh) * 2014-11-02 2017-08-29 纳诺精密医疗有限公司 用于延长释放治疗剂的可植入医药装置
CN108113975A (zh) * 2018-02-02 2018-06-05 中国人民解放军军事科学院军事医学研究院 一种基于涡漩振荡器的plga微球制备方法及其应用
CN109106688A (zh) * 2018-08-22 2019-01-01 丽珠医药集团股份有限公司 一种醋酸奥曲肽微球的制备方法
CN109106688B (zh) * 2018-08-22 2021-08-17 丽珠医药集团股份有限公司 一种醋酸奥曲肽微球的制备方法
CN114174385A (zh) * 2020-05-08 2022-03-11 M技术株式会社 主剂均匀分散的微球和含有其的缓释制剂
CN114174385B (zh) * 2020-05-08 2023-03-14 M技术株式会社 主剂均匀分散的微球和含有其的缓释制剂

Also Published As

Publication number Publication date
BR112016022550B1 (pt) 2023-03-28
EP3125871B1 (en) 2020-10-21
JP6494657B2 (ja) 2019-04-03
EA201691884A1 (ru) 2017-02-28
KR102218655B1 (ko) 2021-02-22
US9943483B2 (en) 2018-04-17
BR112016022550A2 (enExample) 2017-08-15
ES2837044T3 (es) 2021-06-29
CA2944561A1 (en) 2015-10-08
HUE052289T2 (hu) 2021-04-28
SI3125871T1 (sl) 2021-03-31
AU2014389015A1 (en) 2016-09-29
EP3125871A1 (en) 2017-02-08
ZA201607413B (en) 2018-11-28
CN114191538A (zh) 2022-03-18
US20170281547A1 (en) 2017-10-05
CA2944561C (en) 2019-06-18
MX371139B (es) 2020-01-20
EA032580B1 (ru) 2019-06-28
RS61209B1 (sr) 2021-01-29
LT3125871T (lt) 2020-12-28
HRP20210058T1 (hr) 2021-03-05
WO2015149820A1 (en) 2015-10-08
JP2017509661A (ja) 2017-04-06
PL3125871T3 (pl) 2021-04-19
KR20160137608A (ko) 2016-11-30
SMT202000692T1 (it) 2021-01-05
CY1124037T1 (el) 2022-03-24
AU2014389015B2 (en) 2019-05-09
DK3125871T3 (da) 2020-12-21
PT3125871T (pt) 2021-01-06
MX2016012846A (es) 2017-05-09

Similar Documents

Publication Publication Date Title
AU2014389015B2 (en) Preparation of peptide loaded PLGA microspheres with controlled release characteristics
RU2722358C1 (ru) Способ изготовления биоразлагаемых микросфер, отличающихся повышенной стабильностью и устойчивостью при хранении
Lee et al. Poly (lactic‐co‐glycolic acid) devices: Production and applications for sustained protein delivery
Lu et al. Microparticles produced by the hydrogel template method for sustained drug delivery
Zhou et al. Effect of manufacturing variables and raw materials on the composition-equivalent PLGA microspheres for 1-month controlled release of leuprolide
AU2014283692B2 (en) Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
Giles et al. Efficient aqueous remote loading of peptides in poly (lactic-co-glycolic acid)
CN112972388B (zh) 卡利拉嗪释放制剂
CA3112938C (en) Injectable long-acting naltrexone microparticle compositions
Yushu et al. The effect of process variables on the morphology and release characteristics of protein‐loaded PLGA particles
KR101961848B1 (ko) C18:1, c18:1(oh) 또는 c18:2의 장쇄 지방산이 포함된 오일류를 포함한 방출억제제를 적용한 서방출성 마이크로스피어 및 이의 제조방법
Iwata et al. Selection of the solvent system for the preparation of poly (D, L-lactic-co-glycolic acid) microspheres containing tumor necrosis factor-alpha (TNF-α)
Choi et al. Development of drug-loaded PLGA microparticles with different release patterns for prolonged drug delivery
Strack et al. A smart approach to enable preclinical studies in pharmaceutical industry: PLGA-based extended release formulation platform for subcutaneous applications
Schutzman Mechanistic Evaluation of Early Phases of Drug Release From Polymer Microparticles Prepared by Atomization Techniques
HK40051607A (en) Cariprazine release formulations
CN118806705A (zh) 一种制备载促性腺激素释放激素激动剂药物缓释微球的方法和应用
RS56427B1 (sr) Priprema polilaktidnih-poliglikolidnih mikročestica koje imaju sigmoidalni profil oslobađanja

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161130